Terapio

Terapio is a technology company.

Active

Updated: Mar 22, 2026 ·

About

Terapio is a biopharmaceutical company developing therapeutics based on the RLIP76 protein. Its core focus includes medical countermeasures for radiation exposure and chemical threats, enhancing cellular defenses. The company also actively researches novel treatments for inborn errors of metabolism and advanced therapies targeting tumor metabolism.

Casey Cunningham founded Terapio in 2005, with its headquarters in Austin, Texas. The company's inception was driven by the identified therapeutic potential of the RLIP76 protein. This foundational insight propelled Terapio to translate this scientific discovery into practical medical applications.

Terapio's therapeutics aim to benefit civilian populations, military personnel, and first responders, providing crucial protection. The company is committed to pioneering novel treatments that address significant unmet medical needs. Its long-term vision involves continually improving health outcomes across various challenging medical conditions.

Recent News & Mentions

Jul 1, 2015FundingTerapio - Series B Nov 1, 2009FundingTerapio - Series A

Financial History

Terapio has raised $5.8M across 2 funding rounds. Most recently, it raised $780K Series B in July 2015.

Total Raised

$5.8M

Valuation

N/A

Funding Rounds Raised

Date	Round	Lead Investors	Other Investors
Jul 1, 2015	$780K Series B		Santé Ventures
Nov 1, 2009	$5.0M Series A		Santé Ventures

Financial History

Terapio has raised $5.8M across 2 funding rounds.

Total Raised

$5.8M

Valuation

N/A

Deep Dive

Terapio appears to refer to two distinct companies in public sources: a consumer medical‑device brand selling TENS pain‑relief units, and a biotech/biopharma company working on therapeutics related to Rlip76 and metabolic therapies. The summary below treats both entities separately and follows your requested structure so you can pick the relevant profile quickly.

High‑Level Overview

Terapio (consumer medical devices): Terapio sells certified Smart TENS (transcutaneous electrical nerve stimulation) units and related personal pain‑management devices, positioning itself as a medical‑device brand for at‑home relief from minor aches and muscle pain; its product line includes wireless and multi‑mode TENS/EMS units designed in Switzerland and marketed as medically certified personal health devices[2].- Terapio (biopharma): A separate Terapio (sometimes listed as Terapio Corp.) is a biopharmaceutical company based in Austin, Texas, developing therapeutics tied to the Rlip76 protein and pursuing programs in inborn errors of metabolism (IEM) and tumor metabolism, aiming to translate molecular targets into novel treatments[1][4].

Origin Story

Consumer device Terapio: Public product pages emphasize Swiss design and medical certification but do not list founders or founding year on the product site; the brand narrative focuses on delivering clinical TENS therapy for home use without prescription and expanding device features (wireless, multi‑program) to increase usability[2].- Biopharma Terapio: Company listings identify Terapio Corp. as a Texas/Austin‑headquartered biopharma; sources note the company’s focus on Rlip76 biology and metabolic disease programs but do not provide a detailed founding year or founder biographies in the available directory/PatSnap synopses[1][3][4].

Core Differentiators

Consumer device Terapio
Product breadth: Offers wireless TENS and a 3‑in‑1 TENS unit that pairs TENS pain relief with EMS (muscle stimulation) and massage modes to target different needs[2]. - Device features: Multiple therapeutic programs (over 50 in some models), 16 intensity levels and two channels for dual‑site therapy provide flexibility for users[2]. - Certification & design: Marketed as medically certified and designed in Switzerland, which the brand uses to signal quality and regulatory compliance[2].

Biopharma Terapio
Target biology: Focus on Rlip76 (a specific protein) and metabolic pathways provides a niche translational angle versus broader platform plays[1][4]. - Therapeutic focus: Programs include treatments for inborn errors of metabolism and tumor metabolism, indicating both rare‑disease and oncology applications[4]. - IP & development signals: Patent and pipeline listings in PatSnap/Synapse indicate an active R&D and IP footprint consistent with preclinical/early clinical biotech development[3][4].

Role in the Broader Tech/Health Landscape

Consumer device Terapio: Rides the at‑home digital/connected health trend where low‑risk, over‑the‑counter medical devices (TENS/EMS) expand access to non‑pharmacologic pain management; timing aligns with rising consumer interest in wearable and portable therapy solutions and demand for drug‑free pain alternatives[2].- Biopharma Terapio: Operates within the growing focus on metabolic disease biology and targeted oncology metabolism programs; by developing therapies against a specific protein (Rlip76) and IEMs, it fits the broader biotech trend of mechanism‑driven, precision therapeutic development where rare‑disease and tumor‑metabolism niches can attract specialized investment and partnership interest[1][4].

Quick Take & Future Outlook

Consumer device Terapio: Short‑term growth likely depends on retail/online distribution expansion, clinical validation or partnerships with clinicians/physiotherapists, and continuing product iteration (battery life, app integration, electrode tech). If the brand secures visible clinical endorsements or broader channel partnerships, it could scale within DTC and pharmacy channels; absent public funding/leadership disclosure, the brand story will rest on product certification and user experience[2].- Biopharma Terapio: Future progress depends on advancing preclinical programs into clinical trials, generating safety/efficacy data, and securing biopharma partnerships or venture funding—common inflection points for small biotech focused on specific molecular targets. Success in IEMs or tumor‑metabolism indications could make the company an acquisition target or partner for larger pharma pursuing metabolic or oncology pipelines[1][4].

Notes and limitations

Public information conflates two separate entities named Terapio (a consumer TENS device brand and a biotech company); sources cited reflect each and do not provide comprehensive founder or funding detail for either entity[1][2][3][4].- If you want a single, consolidated profile (investor‑style or company deep dive), tell me which Terapio you mean (consumer device vs. biopharma) and I can dig further into corporate filings, patents, clinical trials, distribution channels, leadership bios, funding rounds, or recent press.

Sources

Frequently Asked Questions

How much funding has Terapio raised?

Terapio has raised $5.8M in total across 2 funding rounds.

Who are Terapio's investors?

Terapio's investors include Santé Ventures.